inflammatory breast neoplasms/fatigue

Le lien est enregistré dans le presse-papiers

Des articlesEssais cliniquesBrevets

Choisissez le type de tri

7 résultats

High-dose sequential chemotherapy with recombinant granulocyte colony-stimulating factor and repeated stem-cell support for inflammatory breast cancer patients: does impact on quality of life jeopardize feasibility and acceptability of treatment?

Seuls les utilisateurs enregistrés peuvent traduire des articles

Se connecter S'inscrire

OBJECTIVE This study was designed to investigate the quality of life (QOL) of patients enrolled onto the High-Dose Chemotherapy for Breast Cancer Study Group trial (PEGASE 02), a French pilot multicenter trial of the treatment of inflammatory breast cancer (IBC) aimed at evaluating (1) toxicity and

[A case report of inflammatory breast cancer effectively treated with cis-platinum].

Seuls les utilisateurs enregistrés peuvent traduire des articles

Se connecter S'inscrire

A 50-year-old woman with bilateral inflammatory breast cancer (T4, N1b, M1, Stage IV) underwent right extended radical mastectomy and left modified radical mastectomy following pre-operative administration of carcinostatics (ADM, 5-FU) and irradiation. However, tumor recurrence was observed at the

[A multicenter study of epirubicin-docetaxel(ET)as primary chemotherapy for patients with inflammatory breast cancer(IBC)].

Seuls les utilisateurs enregistrés peuvent traduire des articles

Se connecter S'inscrire

We evaluated the efficacy and safety of the epirubicin plus docetaxel(ET)regimen, which is a combination of active agents given to patients with inflammatory breast cancer(IBC)as a primary therapy. Nineteen patients received ET(60, 60mg/m2) every 3 weeks for 4 courses, and appropriate surgery was

Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.

Seuls les utilisateurs enregistrés peuvent traduire des articles

Se connecter S'inscrire

BACKGROUND Bevacizumab with chemotherapy improves outcomes in patients with metastatic breast cancer (MBC). The purpose of this trial was to determine the activity and safety profile of neoadjuvant bevacizumab with chemotherapy in women with locally advanced breast cancer (LABC). METHODS Between

Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer.

Seuls les utilisateurs enregistrés peuvent traduire des articles

Se connecter S'inscrire

Preclinical data support a role for the IL-6/JAK2/STAT3 signaling pathway in breast cancer. Ruxolitinib is an orally bioavailable receptor tyrosine inhibitor targeting JAK1 and JAK2. We evaluated the safety and efficacy of ruxolitinib in patients with metastatic breast cancer. This was a

Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors.

Seuls les utilisateurs enregistrés peuvent traduire des articles

Se connecter S'inscrire

BACKGROUND The current study was conducted to evaluate the safety and biological activity of dual inhibition of the vascular endothelial growth factor (VEGF) pathway with combined bevacizumab and cediranib (a VEGF receptor tyrosine kinase inhibitor). METHODS This was a 3 + 3 dose escalation study in

Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.

Seuls les utilisateurs enregistrés peuvent traduire des articles

Se connecter S'inscrire

BACKGROUND Lapatinib, the first dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) tyrosine kinases, was approved by the US Food and Drug Administration (FDA) in 2007. It is indicated for use in combination with capecitabine for the

Rejoignez notre
page facebook

Herbal & Natural Medicine

La base de données d'herbes médicinales la plus complète soutenue par la science

Fonctionne en 55 langues
Cures à base de plantes soutenues par la science
Reconnaissance des herbes par image
Carte GPS interactive - étiquetez les herbes sur place (à venir)
Lisez les publications scientifiques liées à votre recherche
Rechercher les herbes médicinales par leurs effets
Organisez vos intérêts et restez à jour avec les nouvelles recherches, essais cliniques et brevets

Tapez un symptôme ou une maladie et lisez des informations sur les herbes qui pourraient aider, tapez une herbe et voyez les maladies et symptômes contre lesquels elle est utilisée.
* Toutes les informations sont basées sur des recherches scientifiques publiées